(Alliance News) - The FTSE 100 closed sharply higher on Thursday, just shy of a new all-time peak, after the Bank of England lowered interest rates with a more 'dovish' vote split than forecast. Read More
(Alliance News) - Stock prices in Europe pushed higher on Thursday, as a lack of tariff tit-for-tat news supported equities, while the Bank of England announced a rate cut which turbocharged the FTSE 100. Read More
(Alliance News) - AstraZeneca PLC on Thursday ended a strong year with better-than-expected fourth quarter earnings and said its pipeline would support further growth in 2025. Read More
(Alliance News) - Stock prices in London opened higher on Thursday, with the absence of new tariff salvos boosting risk appetite, while the pound faded from the USD1.25 mark before a Bank of England decision. Read More
(Alliance News) - London's FTSE 100 is called to open higher on Thursday, with risk appetite returning after a week which has so far been marred by trade war worries. Read More
Indivior PLC - Richmond, Virginia-based maker of medicines to treat substance use disorders - Completes share buyback programme begun in July. Indivior buys back 9.4 million shares at average GBP8.25, worth GBP77.7 million, about USD100.0 million, in total. The buyback was run by Morgan Stanley & Co International PLC. Last week, Indivior promoted David Wheadon to chair, starting immediately. Wheadon joined the Indivior board in June last year. Wheadon is a medical doctor who worked for GlaxoSmithKline, now GSK PLC, and Eli Lilly & Co. Until 2019, he was senior vice president of global regulatory affairs, patient safety & quality assurance at AstraZeneca PLC. Read More
(Alliance News) - AstraZeneca PLC on Monday said Imfinzi has been recommended for approval in the EU as monotherapy for limited-stage small cell lung cancer. Read More
(Alliance News) - European equities are set to tumble at the start of the week, while the dollar powered higher after US President Donald Trump imposed tariffs on some of the nation's major trading partners. Read More
(Alliance News) - AstraZeneca PLC has cancelled a planned GBP450 million investment in a vaccine manufacturing plant in Merseyside, saying Labour failed to match the previous government's offer of support. Read More
(Alliance News) - The following is a round-up of London-listed company director and manager changes announced in the past week and not separately reported by Alliance News: Read More
(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Monday celebrated another approval of their cancer drug Enhertu. Read More
(Alliance News) - Stocks were called to open higher in London on Friday morning, although UK consumer confidence has reportedly suffered a steep fall in recent weeks. Read More
(Alliance News) - AstraZeneca PLC on Thursday announced a USD570 million investment in Canada, creating more than 700 jobs, across all areas of the business. Read More
(Alliance News) - The following London-listed shares received analyst recommendations on Monday morning and on Friday: Read More
(Alliance News) - AstraZeneca PLC on Monday said Datroway has been approved in the US for patients with a type of breast cancer. Read More
(Alliance News) - The FTSE 100 was called to open down on Monday morning, ahead of Donald Trump's first day as 47th US president. Read More
(Alliance News) - AstraZeneca PLC on Friday said its drug Calquence, in combination with chemoimmunotherapy, has received approval from the US Food & Drug Administration for the treatment of adult patients with previously untreated mantle cell lymphoma who are ineligible for stem cell transplantation. Read More
(Alliance News) - Stocks were called to open higher on Friday after China recorded one of its slowest rates of economic growth in decades last year, despite outperforming consensus in the fourth quarter. Read More
Hutchmed (China) Ltd - Hong Kong-based biopharmaceutical firm - Says its lung cancer treatment Orpathys has received full approval in China for adult patients. It has been developed in collaboration with AstraZeneca PLC, with Hutchmed leading in China and AZ leading outside of China. The drug was approved by the China National Medical Products Administration for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer. The approval was based on data from the confirmatory phase 3B clinical trial. Read More